Exercise-induced  ||| S:0 E:17 ||| JJ
increases  ||| S:17 E:27 ||| NNS
in  ||| S:27 E:30 ||| IN
inflammatory  ||| S:30 E:43 ||| JJ
cytokines  ||| S:43 E:53 ||| NN
in  ||| S:53 E:56 ||| IN
muscle  ||| S:56 E:63 ||| NN
and  ||| S:63 E:67 ||| CC
blood  ||| S:67 E:73 ||| NN
of  ||| S:73 E:76 ||| IN
horses  ||| S:76 E:83 ||| JJ
Studies  ||| S:83 E:91 ||| NNS
have  ||| S:91 E:96 ||| VBP
demonstrated  ||| S:96 E:109 ||| VBN
increases  ||| S:109 E:119 ||| NNS
in  ||| S:119 E:122 ||| IN
mRNA  ||| S:122 E:127 ||| JJ
expression  ||| S:127 E:138 ||| NN
for  ||| S:138 E:142 ||| IN
inflammatory  ||| S:142 E:155 ||| JJ
cytokines  ||| S:155 E:165 ||| NNS
following  ||| S:165 E:175 ||| VBG
exercise  ||| S:175 E:184 ||| NN
in  ||| S:184 E:187 ||| IN
horses  ||| S:187 E:194 ||| NNS
and  ||| S:194 E:198 ||| CC
have  ||| S:198 E:203 ||| VBP
suggested  ||| S:203 E:213 ||| VBN
those  ||| S:213 E:219 ||| DT
markers  ||| S:219 E:227 ||| NN
of  ||| S:227 E:230 ||| IN
inflammation  ||| S:230 E:243 ||| NNS
may  ||| S:243 E:247 ||| MD
play  ||| S:247 E:252 ||| VB
a  ||| S:252 E:254 ||| DT
role  ||| S:254 E:259 ||| NN
in  ||| S:259 E:262 ||| IN
delayed  ||| S:262 E:270 ||| JJ
onset  ||| S:270 E:276 ||| NN
muscle  ||| S:276 E:283 ||| NN
soreness ||| S:283 E:291 ||| NN
.  ||| S:291 E:293 ||| .
However ||| S:293 E:300 ||| RB
,  ||| S:300 E:302 ||| ,
measurement  ||| S:302 E:314 ||| NN
of  ||| S:314 E:317 ||| IN
mRNA  ||| S:317 E:322 ||| JJ
expression  ||| S:322 E:333 ||| NN
in  ||| S:333 E:336 ||| IN
white  ||| S:336 E:342 ||| JJ
blood  ||| S:342 E:348 ||| NN
cells  ||| S:348 E:354 ||| NNS
is  ||| S:354 E:357 ||| VBZ
an  ||| S:357 E:360 ||| DT
indirect  ||| S:360 E:369 ||| JJ
method ||| S:369 E:375 ||| NN
.  ||| S:375 E:377 ||| .
No  ||| S:377 E:380 ||| DT
studies  ||| S:380 E:388 ||| NNS
to  ||| S:388 E:391 ||| TO
date  ||| S:391 E:396 ||| NN
have  ||| S:396 E:401 ||| VBP
documented  ||| S:401 E:412 ||| VBN
the  ||| S:412 E:416 ||| DT
cytokine  ||| S:416 E:425 ||| JJ
response  ||| S:425 E:434 ||| NN
to  ||| S:434 E:437 ||| TO
exercise  ||| S:437 E:446 ||| VB
directly  ||| S:446 E:455 ||| RB
in  ||| S:455 E:458 ||| IN
muscle  ||| S:458 E:465 ||| NN
in  ||| S:465 E:468 ||| IN
horses ||| S:468 E:474 ||| NNS
.  ||| S:474 E:476 ||| .
This  ||| S:476 E:481 ||| DT
study  ||| S:481 E:487 ||| NN
tested  ||| S:487 E:494 ||| VBD
the  ||| S:494 E:498 ||| DT
hypothesis  ||| S:498 E:509 ||| NN
that  ||| S:509 E:514 ||| IN
exercise  ||| S:514 E:523 ||| NN
increases  ||| S:523 E:533 ||| NNS
cytokine  ||| S:533 E:542 ||| VBP
markers  ||| S:542 E:550 ||| VBN
of  ||| S:550 E:553 ||| IN
inflammation  ||| S:553 E:566 ||| NN
in  ||| S:566 E:569 ||| IN
blood  ||| S:569 E:575 ||| NN
and  ||| S:575 E:579 ||| CC
muscle ||| S:579 E:585 ||| NN
.  ||| S:585 E:587 ||| .
Blood  ||| S:587 E:593 ||| NN
and  ||| S:593 E:597 ||| CC
muscle  ||| S:597 E:604 ||| NN
biopsies  ||| S:604 E:613 ||| NNS
were  ||| S:613 E:618 ||| VBD
obtained  ||| S:618 E:627 ||| VBN
from  ||| S:627 E:632 ||| IN
4  ||| S:632 E:634 ||| CD
healthy ||| S:634 E:641 ||| JJ
,  ||| S:641 E:643 ||| ,
unfit  ||| S:643 E:649 ||| FW
Standardbred  ||| S:649 E:662 ||| FW
mares  ||| S:662 E:668 ||| FW
( ||| S:668 E:669 ||| -LRB-
âˆ¼  ||| S:669 E:671 ||| CD
500  ||| S:671 E:675 ||| CD
kg ||| S:675 E:677 ||| CD
) ||| S:677 E:678 ||| -RRB-
.  ||| S:678 E:680 ||| .
The  ||| S:680 E:684 ||| DT
randomised  ||| S:684 E:695 ||| JJ
crossover  ||| S:695 E:705 ||| JJ
experiment  ||| S:705 E:716 ||| NN
was  ||| S:716 E:720 ||| VBD
performed  ||| S:720 E:730 ||| VBN
with  ||| S:730 E:735 ||| IN
the  ||| S:735 E:739 ||| DT
investigators  ||| S:739 E:753 ||| NNS
performing  ||| S:753 E:764 ||| VBG
the  ||| S:764 E:768 ||| DT
analysis  ||| S:768 E:777 ||| NN
blind  ||| S:777 E:783 ||| NN
to  ||| S:783 E:786 ||| TO
the  ||| S:786 E:790 ||| DT
treatment ||| S:790 E:799 ||| NN
.  ||| S:799 E:801 ||| .
Each  ||| S:801 E:806 ||| DT
horse  ||| S:806 E:812 ||| NN
underwent  ||| S:812 E:822 ||| VBD
either  ||| S:822 E:829 ||| DT
incremental  ||| S:829 E:841 ||| JJ
exercise  ||| S:841 E:850 ||| NN
test  ||| S:850 E:855 ||| NN
( ||| S:855 E:856 ||| -LRB-
GXT ||| S:856 E:859 ||| NNP
)  ||| S:859 E:861 ||| -RRB-
or  ||| S:861 E:864 ||| CC
standing  ||| S:864 E:873 ||| VBG
parallel  ||| S:873 E:882 ||| JJ
control  ||| S:882 E:890 ||| NN
with  ||| S:890 E:895 ||| IN
the  ||| S:895 E:899 ||| DT
trials  ||| S:899 E:906 ||| NNS
performed  ||| S:906 E:916 ||| VBD
one  ||| S:916 E:920 ||| CD
month  ||| S:920 E:926 ||| NN
apart ||| S:926 E:931 ||| RB
.  ||| S:931 E:933 ||| .
During  ||| S:933 E:940 ||| IN
the  ||| S:940 E:944 ||| DT
GXT  ||| S:944 E:948 ||| NNP
horses  ||| S:948 E:955 ||| NNS
ran  ||| S:955 E:959 ||| VBD
on  ||| S:959 E:962 ||| IN
a  ||| S:962 E:964 ||| DT
treadmill  ||| S:964 E:974 ||| NN
( ||| S:974 E:975 ||| -LRB-
1  ||| S:975 E:977 ||| CD
m ||| S:977 E:978 ||| CD
/ ||| S:978 E:979 ||| CD
s  ||| S:979 E:981 ||| NN
increases  ||| S:981 E:991 ||| VBZ
each  ||| S:991 E:996 ||| DT
min  ||| S:996 E:1000 ||| NN
until  ||| S:1000 E:1006 ||| IN
fatigue ||| S:1006 E:1013 ||| NN
,  ||| S:1013 E:1015 ||| ,
6 ||| S:1015 E:1016 ||| CD
%  ||| S:1016 E:1018 ||| NN
grade ||| S:1018 E:1023 ||| NN
) ||| S:1023 E:1024 ||| -RRB-
.  ||| S:1024 E:1026 ||| .
Blood  ||| S:1026 E:1032 ||| NN
and  ||| S:1032 E:1036 ||| CC
muscle  ||| S:1036 E:1043 ||| NN
biopsies  ||| S:1043 E:1052 ||| NNS
were  ||| S:1052 E:1057 ||| VBD
obtained  ||| S:1057 E:1066 ||| VBN
30  ||| S:1066 E:1069 ||| CD
min  ||| S:1069 E:1073 ||| NN
before  ||| S:1073 E:1080 ||| IN
exercise ||| S:1080 E:1088 ||| NN
,  ||| S:1088 E:1090 ||| ,
immediately  ||| S:1090 E:1102 ||| RB
after  ||| S:1102 E:1108 ||| IN
exercise  ||| S:1108 E:1117 ||| NN
and  ||| S:1117 E:1121 ||| CC
at  ||| S:1121 E:1124 ||| IN
0.5 ||| S:1124 E:1127 ||| CD
,  ||| S:1127 E:1129 ||| ,
1 ||| S:1129 E:1130 ||| CD
,  ||| S:1130 E:1132 ||| ,
2 ||| S:1132 E:1133 ||| CD
,  ||| S:1133 E:1135 ||| ,
6  ||| S:1135 E:1137 ||| CD
and  ||| S:1137 E:1141 ||| CC
24  ||| S:1141 E:1144 ||| CD
h  ||| S:1144 E:1146 ||| JJ
post  ||| S:1146 E:1151 ||| NN
GXT  ||| S:1151 E:1155 ||| NNP
or  ||| S:1155 E:1158 ||| CC
at  ||| S:1158 E:1161 ||| IN
matched  ||| S:1161 E:1169 ||| JJ
time  ||| S:1169 E:1174 ||| NN
points  ||| S:1174 E:1181 ||| NNS
during  ||| S:1181 E:1188 ||| IN
the  ||| S:1188 E:1192 ||| DT
parallel  ||| S:1192 E:1201 ||| JJ
control  ||| S:1201 E:1209 ||| NN
trials ||| S:1209 E:1215 ||| NNS
.  ||| S:1215 E:1217 ||| .
Samples  ||| S:1217 E:1225 ||| NNS
were  ||| S:1225 E:1230 ||| VBD
analysed  ||| S:1230 E:1239 ||| VBN
using  ||| S:1239 E:1245 ||| VBG
real  ||| S:1245 E:1250 ||| JJ
time-PCR  ||| S:1250 E:1259 ||| NN
for  ||| S:1259 E:1263 ||| IN
measurement  ||| S:1263 E:1275 ||| NN
of  ||| S:1275 E:1278 ||| IN
mRNA  ||| S:1278 E:1283 ||| JJ
expression  ||| S:1283 E:1294 ||| NN
of  ||| S:1294 E:1297 ||| IN
interferon-gamma  ||| S:1297 E:1314 ||| NNP
( ||| S:1314 E:1315 ||| -LRB-
IFN-gamma ||| S:1315 E:1324 ||| NNP
) ||| S:1324 E:1325 ||| -RRB-
,  ||| S:1325 E:1327 ||| ,
tumour  ||| S:1327 E:1334 ||| FW
necrosis  ||| S:1334 E:1343 ||| FW
factor-alpha  ||| S:1343 E:1356 ||| FW
( ||| S:1356 E:1357 ||| -LRB-
TNF-alpha ||| S:1357 E:1366 ||| NNP
) ||| S:1366 E:1367 ||| -RRB-
,  ||| S:1367 E:1369 ||| ,
interleukin-6  ||| S:1369 E:1383 ||| NNP
( ||| S:1383 E:1384 ||| -LRB-
IL-6 ||| S:1384 E:1388 ||| NNP
)  ||| S:1388 E:1390 ||| -RRB-
and  ||| S:1390 E:1394 ||| CC
interleukin-1  ||| S:1394 E:1408 ||| NNP
( ||| S:1408 E:1409 ||| -LRB-
IL-1 ||| S:1409 E:1413 ||| NNP
) ||| S:1413 E:1414 ||| -RRB-
.  ||| S:1414 E:1416 ||| .
Data  ||| S:1416 E:1421 ||| NNP
were  ||| S:1421 E:1426 ||| VBD
analysed  ||| S:1426 E:1435 ||| VBN
using  ||| S:1435 E:1441 ||| VBG
t  ||| S:1441 E:1443 ||| JJ
tests  ||| S:1443 E:1449 ||| NNS
with  ||| S:1449 E:1454 ||| IN
the  ||| S:1454 E:1458 ||| DT
null  ||| S:1458 E:1463 ||| JJ
hypothesis  ||| S:1463 E:1474 ||| NN
rejected  ||| S:1474 E:1483 ||| VBD
when  ||| S:1483 E:1488 ||| WRB
P  ||| S:1488 E:1490 ||| NN
< ||| S:1490 E:1492 ||| SYM
0.10 ||| S:1492 E:1496 ||| CD
.  ||| S:1496 E:1498 ||| .
There  ||| S:1498 E:1504 ||| EX
were  ||| S:1504 E:1509 ||| VBD
no  ||| S:1509 E:1512 ||| DT
changes  ||| S:1512 E:1520 ||| NNS
( ||| S:1520 E:1521 ||| -LRB-
P  ||| S:1521 E:1523 ||| NNP
>  ||| S:1523 E:1525 ||| CD
0.10 ||| S:1525 E:1529 ||| CD
)  ||| S:1529 E:1531 ||| -RRB-
in  ||| S:1531 E:1534 ||| IN
IL-1 ||| S:1534 E:1538 ||| NNP
,  ||| S:1538 E:1540 ||| ,
IL-6 ||| S:1540 E:1544 ||| NNP
,  ||| S:1544 E:1546 ||| ,
IFN-gamma  ||| S:1546 E:1556 ||| JJ
or  ||| S:1556 E:1559 ||| CC
TNF-alpha  ||| S:1559 E:1569 ||| JJ
during  ||| S:1569 E:1576 ||| IN
control ||| S:1576 E:1583 ||| NN
.  ||| S:1583 E:1585 ||| .
Exercise  ||| S:1585 E:1594 ||| VB
induced  ||| S:1594 E:1602 ||| VBN
significant  ||| S:1602 E:1614 ||| JJ
increases  ||| S:1614 E:1624 ||| NNS
in  ||| S:1624 E:1627 ||| IN
IFN-gamma ||| S:1627 E:1636 ||| NNP
,  ||| S:1636 E:1638 ||| ,
IL1  ||| S:1638 E:1642 ||| NNP
and  ||| S:1642 E:1646 ||| CC
TNF-alpha  ||| S:1646 E:1656 ||| JJ
in  ||| S:1656 E:1659 ||| IN
blood  ||| S:1659 E:1665 ||| NN
and  ||| S:1665 E:1669 ||| CC
significant  ||| S:1669 E:1681 ||| JJ
increases  ||| S:1681 E:1691 ||| NNS
in  ||| S:1691 E:1694 ||| IN
IFN-gamma ||| S:1694 E:1703 ||| NNP
,  ||| S:1703 E:1705 ||| ,
IL-6  ||| S:1705 E:1710 ||| NNP
and  ||| S:1710 E:1714 ||| CC
TNF-alpha  ||| S:1714 E:1724 ||| JJ
in  ||| S:1724 E:1727 ||| IN
muscle ||| S:1727 E:1733 ||| NN
.  ||| S:1733 E:1735 ||| .
There  ||| S:1735 E:1741 ||| EX
were  ||| S:1741 E:1746 ||| VBD
no  ||| S:1746 E:1749 ||| DT
significant  ||| S:1749 E:1761 ||| JJ
changes  ||| S:1761 E:1769 ||| NNS
in  ||| S:1769 E:1772 ||| IN
mRNA  ||| S:1772 E:1777 ||| JJ
expression  ||| S:1777 E:1788 ||| NN
of  ||| S:1788 E:1791 ||| IN
IL-1  ||| S:1791 E:1796 ||| CD
in  ||| S:1796 E:1799 ||| IN
muscle  ||| S:1799 E:1806 ||| NN
or  ||| S:1806 E:1809 ||| CC
IL-6  ||| S:1809 E:1814 ||| CD
in  ||| S:1814 E:1817 ||| IN
blood  ||| S:1817 E:1823 ||| NN
following  ||| S:1823 E:1833 ||| VBG
the  ||| S:1833 E:1837 ||| DT
GXT ||| S:1837 E:1840 ||| NNP
.  ||| S:1840 E:1842 ||| .
These  ||| S:1842 E:1848 ||| DT
cytokine  ||| S:1848 E:1857 ||| JJ
markers  ||| S:1857 E:1865 ||| NN
of  ||| S:1865 E:1868 ||| IN
inflammation  ||| S:1868 E:1881 ||| VBG
all  ||| S:1881 E:1885 ||| DT
returned  ||| S:1885 E:1894 ||| VBN
to  ||| S:1894 E:1897 ||| TO
preGXT  ||| S:1897 E:1904 ||| JJ
levels  ||| S:1904 E:1911 ||| NNS
by  ||| S:1911 E:1914 ||| IN
24  ||| S:1914 E:1917 ||| CD
h  ||| S:1917 E:1919 ||| JJ
post  ||| S:1919 E:1924 ||| NN
GXT ||| S:1924 E:1927 ||| NNP
.  ||| S:1927 E:1929 ||| .
High  ||| S:1929 E:1934 ||| JJ
intensity  ||| S:1934 E:1944 ||| NN
exercise  ||| S:1944 E:1953 ||| NN
results  ||| S:1953 E:1961 ||| NNS
in  ||| S:1961 E:1964 ||| IN
a  ||| S:1964 E:1966 ||| DT
transient  ||| S:1966 E:1976 ||| JJ
increase  ||| S:1976 E:1985 ||| NN
in  ||| S:1985 E:1988 ||| IN
the  ||| S:1988 E:1992 ||| DT
expression  ||| S:1992 E:2003 ||| NN
of  ||| S:2003 E:2006 ||| IN
inflammatory  ||| S:2006 E:2019 ||| JJ
cytokines  ||| S:2019 E:2029 ||| NN
in  ||| S:2029 E:2032 ||| IN
muscle  ||| S:2032 E:2039 ||| NN
and  ||| S:2039 E:2043 ||| CC
blood ||| S:2043 E:2048 ||| NN
.  ||| S:2048 E:2050 ||| .
